Equity · Healthcare

TERN

NMS

Terns Pharmaceuticals (TERN)

Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for TERN to draw a line in its place.

Terns Pharmaceuticals (TERN) insider trades

SEC Form 4

TERN has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 5 May 2026.

Date Insider Type Shares Value

01 Apr 2026 Kuriakose Emil Chief Medical Officer Sell 942 $50K

16 Mar 2026 Burroughs Amy L. Chief Executive Officer Sell 14,583 $681K

17 Feb 2026 Burroughs Amy L. Chief Executive Officer Sell 14,583 $572K

15 Jan 2026 Burroughs Amy L. Chief Executive Officer Sell 68,749 $2.55M

05 Jan 2026 Burroughs Amy L. Chief Executive Officer Sell 71,339 $2.72M

02 Jan 2026 Kuriakose Emil Chief Medical Officer Sell 1,155 $45K

04 Nov 2025 Quigley Jill M. Sell 24,520 $441K

01 Oct 2025 Kuriakose Emil Chief Medical Officer Sell 944 $7K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value

05 May 2026 Kuriakose Emil Chief Medical Officer Other 106,515 $5.65M

05 May 2026 Burroughs Amy L. Chief Executive Officer Other 304,933 $16.16M

05 May 2026 Gengos Andrew Chief Financial Officer Other 109,253 $5.79M

16 Mar 2026 Burroughs Amy L. Chief Executive Officer Option exercise 14,583 $68K

17 Feb 2026 Burroughs Amy L. Chief Executive Officer Option exercise 14,583 $68K

15 Jan 2026 Burroughs Amy L. Chief Executive Officer Option exercise 68,749 $319K

14 Jan 2026 Kuriakose Emil Chief Medical Officer Award 56,250

14 Jan 2026 Burroughs Amy L. Chief Executive Officer Award 150,000

14 Jan 2026 Gengos Andrew Chief Financial Officer Award 68,750

05 Jan 2026 Burroughs Amy L. Chief Executive Officer Option exercise 150,000

02 Jan 2026 Burroughs Amy L. Chief Executive Officer Option exercise 21,551 $100K

04 Nov 2025 Quigley Jill M. Option exercise 24,520 $227K

Terns Pharmaceuticals (TERN) earnings

SEC EDGAR

Terns Pharmaceuticals last reported earnings on 31 Dec 2025 for FY 2025, with EPS of −$1.03; no next date is announced in SEC filings yet.

Date Period EPS Revenue

31 Dec 2025 FY 2025 −$1.03 —

30 Sep 2025 Q3 2025 −$0.27 —

30 Jun 2025 Q2 2025 −$0.26 —

31 Mar 2025 Q1 2025 −$0.26 —

31 Dec 2024 FY 2024 −$1.12 —

30 Sep 2024 Q3 2024 −$0.28 —

30 Jun 2024 Q2 2024 −$0.31 —

31 Mar 2024 Q1 2024 −$0.30 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Terns Pharmaceuticals (TERN): frequently asked questions

From live data

Have Terns Pharmaceuticals insiders bought or sold shares recently?

No Terns Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 5 May 2026 (SEC Form 4).

How many institutions hold Terns Pharmaceuticals?

0 of the 45 institutional funds we track reported a Terns Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

When did Terns Pharmaceuticals last report earnings?

Terns Pharmaceuticals last reported earnings on 31 Dec 2025 for FY 2025, with EPS of −$1.03; no next date is announced in SEC filings yet.

What exchange is Terns Pharmaceuticals listed on?

Terns Pharmaceuticals trades on NMS under the ticker TERN.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

TradingViewthe price chart widget, drawn by TradingView from their own data
SEC EDGARSEC EDGAR 13F filings